2. Media Briefing Saturday, April 16th 10:00 am – Media briefing begins Announcement of poster winners and a short presentation from some of the winning authors Introduction of Yehuda Handelsman, MD, FACP, FACE, FNLA as the new President of AACE 10:25 am – Floor opens to questions from the media 10:30 am – Media Briefing adjourns

3. OMENTECTOMY ADDED TO ROUX-EN-Y GASTRIC BYPASS IMPROVES GLUCOSE AND ADIPOKINES AT 90 DAYS: A RANDOMIZED, CONTROLLED TRIAL TH Dillard 1, JQ Purnell 1, MD Smith 2, J Laut 2, W Raum 2, D Hong 3, E Patterson 2 1.Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition. Oregon Health & Science University, Portland, OR 2.Department of Surgery, Legacy Good Samaritan Hospital, Portland, OR; 3.Department of Surgery, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada AACE 2011

5.  Coagulation abnormalities in Diabetes Mellitus type 2 and microvascular complications Ritu Madan MD

6. Study design  Single center case control study between 2006-2008  60 patients with diabetes, 20 with and 40 without complications (nephropathy, retinopathy, neuropathy)  Equal number of males and females  Evaluation of major coagulation parameters

7. RESULTS

8. Results (contd.) DMDM WITH COMPLICATIONS P-valueSignificance Platelet Count1.93±0.602.06±0.620.43NS PT14.1±0.9113.17±1.020.5NS PTT34.5±0.7634.6±1.020.64NS Fibrinogen239.5±36.7259.37±40.850.07NS AT III95.8±14.7195.82±10.890.99NS Protein C101.85±16.499.11±23.770.68NS Protein S63.05±16.8551.59±10.70.002S PAI-137.15±15.1848.65±22.90.04S vWF123.19±29.63155.57±34.610.007S Factor V98.65±3.4398.7±4.390.9NS Factor VIII97.37±5.9097.98±3.90.6NS Factor IX98.9±3.6499.4±1.580.3NS

9. Conclusions  Microvascular complications of Type-2 Diabetes are associated with changes in coagulation parameters.  Differences in coagulation parameters were seen in diabetics with complications of nephropathy and retinopathy compared to diabetics without these complications.  The magnitude of the coagulation abnormalities is unlikely to cause symptomatic thrombotic events and hence may be clinically silent.